ROBERT L. CAPIZZI, M.D.; JOSEPH R. BERTINO, M.D.
Supported by grants CA05138 and CA08341, U.S. Public Health Service, Washington, D.C. Dr. Bertino is a career development awardee (1-K3-CA8853) of the National Cancer Institute, Bethesda, Md.
▸Requests for reprints should be addressed to Joseph R. Bertino, M.D., Department of Medicine, Yale University School of Medicine, 333 Cedar St., New Haven, Conn. 06510
CAPIZZI R., BERTINO J.; Methotrexate Therapy of Wegener's Granulomatosis. Ann Intern Med. 1971;74:74-79. doi: 10.7326/0003-4819-74-1-74
Download citation file:
Published: Ann Intern Med. 1971;74(1):74-79.
Two patients with advanced Wegener's granulomatosis, one with nose, sinus, and skin involvement and the other with pulmonary, renal, and skin involvement, experienced marked improvement with intermittent methotrexate therapy. Initial treatment consisted of weekly intravenous injections of 50 mg. This was subsequently decreased to 15 and 25 mg as a single, weekly oral dose. Responses consisted of marked and rapid subjective relief of symptoms, healing of skin lesions, total clearing of pulmonary infiltrates, and lack of progression of nasal, sinus, and renal lesions. Remission of the disease, for more than 30 and 26 months, respectively, has occurred without evidence of oral or hematologic toxicity of methotrexate.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Nephrology, Pulmonary/Critical Care, Rheumatology, Autoimmune Kidney Disease, Vasculitides.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only